These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24955377)

  • 21. Cyclic Peptide Mimotopes for the Detection of Serum Anti-ATIC Autoantibody Biomarker in Hepato-Cellular Carcinoma.
    Heo CK; Hwang HM; Lim WH; Lee HJ; Yoo JS; Lim KJ; Cho EW
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Jirun P; Zhang G; Kim HK; Ha SA; Zhongtian J; Shishi Q; Zhuqingqing C; Lei G; Yoo J; Kim S; Park YG; Wang J; Yang Y; Xu Z; Huang Z; Lee YK; Song EY; Kim JW
    Dis Markers; 2011; 30(6):307-15. PubMed ID: 21725159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis.
    Xiao J; Long F; Peng T; Hu LB; Cai H; Chen R; Chen WL
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3302-3310. PubMed ID: 31081083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma.
    Jiang C; Zhang Y; Yu HF; Yu XT; Zhou SJ; Tan YF
    Tumour Biol; 2012 Dec; 33(6):2167-72. PubMed ID: 22941466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
    Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
    Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens.
    Koziol JA; Imai H; Dai L; Zhang JY; Tan EM
    Cancer Immunol Immunother; 2018 May; 67(5):835-841. PubMed ID: 29497780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
    Okada R; Otsuka Y; Wakabayashi T; Shinoda M; Aoki T; Murakami M; Arizumi S; Yamamoto M; Aramaki O; Takayama T; Wakiyama S; Yanaga K; Amikura K; Kaneko H; Shimada H
    Int J Cancer; 2020 Nov; 147(9):2578-2586. PubMed ID: 32574375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma.
    Nomura F; Sogawa K; Noda K; Seimiya M; Matsushita K; Miura T; Tomonaga T; Yoshitomi H; Imazeki F; Takizawa H; Mogushi K; Miyazaki M; Yokosuka O
    Biochem Biophys Res Commun; 2012 May; 421(4):837-43. PubMed ID: 22554520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
    Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
    Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
    J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
    Wang J; Xu Y; Zhao H; Zhang X
    J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Value of Serum SMP30 and Anti-SMP30 Antibody in Hepatocellular Carcinoma.
    Zheng SX; Xiang BD; Long JM; Qu C; Mo ZJ; Li K; Zhuang Y; Lv ZL; Zhou SF
    Lab Med; 2018 Jul; 49(3):203-210. PubMed ID: 29562243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.
    El-Shal AS; Zidan HE; Rashad NM; Wadea FM
    Cytokine; 2017 Aug; 96():75-86. PubMed ID: 28371666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma.
    Wu CS; Yen CJ; Chou RH; Li ST; Huang WC; Ren CT; Wu CY; Yu YL
    PLoS One; 2012; 7(7):e39466. PubMed ID: 22808038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system.
    Liu H; Zhang J; Wang S; Pang Z; Wang Z; Zhou W; Wu M
    Cancer Epidemiol; 2012 Feb; 36(1):82-8. PubMed ID: 22018955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
    Imai H; Nakano Y; Kiyosawa K; Tan EM
    Cancer; 1993 Jan; 71(1):26-35. PubMed ID: 8380118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.
    Hong Y; Long J; Li H; Chen S; Liu Q; Zhang B; He X; Wang Y; Li H; Li Y; Zhang T; Lu C; Yan H; Zhang M; Li Q; Cao B; Bai Z; Wang J; Zhang Z; Zhu S; Zheng J; Ou X; Ma H; Jia J; You H; Wang S; Huang J
    EBioMedicine; 2015 May; 2(5):438-46. PubMed ID: 26137588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.